Turkey: Importing Pharmaceuticals To The Turkish Market

Given the potential risks posed to public health, the pharmaceutical sector is one of the most strictly regulated sectors in many countries, including Turkey. In recent years, the importation of foreign pharmaceutical product has grown immensely in Turkey. Manufacture and handling of pharmaceuticals in the distribution chain must strictly conform with detailed regulations and is controlled by national, as well as international, authorities. It is important to retain control over product quality standards and prevent illicit trade.

Turkish regulations outline three ways to import a pharmaceutical into Turkey:

  • Market consumption of licensed products.
  • Patient Sales/Named Patient Program.
  • Compassionate Use.

The most common approach to importing pharmaceuticals to the Turkish commercial market is through the first method. The other two avenues are not intended for bringing pharmaceuticals to the commercial market.

Market Consumption of Licensed Products

Importing pharmaceutical products through the licensing method is the quickest and most reliable option. The Turkish Pharmaceutical and Medical Device Institution ("Institution"), within the Ministry of Health ("Ministry"), is responsible for granting licenses to pharmaceutical products. These licenses are granted under the Licensing Regulation on Human Medicinal Products ("Licensing Regulation"), which outlines the documents and information required. Licenses from the Ministry include permission to import the pharmaceutical product into Turkey.

Pharmaceutical products cannot be launched on the market in Turkey before obtaining a license from the Ministry (Article 5 of the Licensing Regulation; Article 3 of the Pharmaceuticals and Medical Preparations Act). Since the legislative regime prohibits importation of unapproved new drugs into Turkey, importing drugs which lack this Ministry approval violate the law, whether they are for personal use or otherwise.

Importers of pharmaceutical products and active substances must also obtain a certificate of control from the Ministry, as per the Communiqué on Import of Certain Products that are Audited by the Ministry of Health (Communiqué No: 2012/20).

Named Patient Sales

Some pharmaceuticals, especially those critical for treatment of rare or serious diseases such as cancer, may be quite difficult to access due to problems related to obtaining licenses, pricing, and reimbursement of Social Security Institution ("Institution"). The named patient sales approach allows patients in Turkey to access these medicines, under the responsibility of their physician.

This supply methods has grown enormously in recent years, developing into a market worth approximately TRY 1.2 billion (USD 450 million) annually. The patient must pay for the pharmaceutical themselves if is not deemed to be one which the Institution will reimburse for. In this case, affordability issues can arise for patients with serious diseases who need expensive treatments.

The Ministry published a Guideline ("Guideline"), outlining import principles for pharmaceutical products.1 Accordingly, to import a pharmaceutical product in the way, it must be either:

  • Unlicensed in Turkey, or
  • If the Ministry has granted a license:

    • The product is not produced in Turkey
    • The product could not be found in the Turkish market.

The pharmaceutical product must be necessary for the patient's treatment and be approved by the Ministry. To obtain Ministry approval, the physician must provide a prescription for the patient.

Debate exists about the Turkish Pharmacists Association's exclusive authority to import pharmaceutical products under the patient sales approach. The Guideline states that the Association is the only organization authorized to import products which are registered in the "Imported Pharmaceuticals Provision System". Authorization was later granted to certain pharmaceutical warehouses under a by-law. However, the by-law is currently subject to a cancellation action and the Council of State has granted a preliminary injunction which prevents it being applied during the cancellation action. These proceedings are ongoing and pending a final decision from the Council of State.

Compassionate Use Program

The Ministry's Guideline outlines requirements for the Compassionate Use Program. However, this alternative is quite strict. To date, only around 20 pharmaceuticals have been permitted to enter the Turkish market via this approach.

The Guideline2 states that this alternative aims to provide free of charge pharmaceuticals, which are not registered in Turkey, to patients which meet all of the following criteria:

  • For whom treatment has failed with existing accessible licensed products.
  • Who suffer from a serious or urgent life-threatening disease.
  • Have not been included in the scope of clinical trials.

The program only includes pharmaceuticals which have completed at least Phase II studies and have initiated Phase III studies across the world. However, an exception exists for scientifically justifiable and very rare exceptional cases. Studies are not required to be conducted in Turkey.

The patient's treating physician must make a written commitment taking full responsibility for including the patient in this program and submit this commitment to the Ministry.

The program is not a clinical trial and the physician conducting the program is not allowed to receive any payment, under any name. The program does not aim to collect information about drug efficacy. Even if such information is collected, it cannot be used in the Ministry's license registration procedures.

The pharmaceutical may be imported to Turkey either by the pharmaceutical company's subsidiary or a clinical research organization ("CRO") with permission from the Ministry. Once the product is brought to Turkey, the Ministry grants another permit to the importer (the CRO or subsidiary) for products to clear customs. For this permit, the Ministry wishes to see an invoice for the product issued in the name of the CRO or subsidiary, issued by the pharmaceutical company.

The critical point for pharmaceutical manufacturers is that they cannot cease to supply the product ex parte. The patient's doctor should file quarterly reports and if these indicate that the patient benefits from the drug, the pharmaceutical manufacturer must continue to send the products, until it obtains a license in Turkey

Since the compassionate use program allows access to drugs which are not yet approved, it naturally involves inherent risks. For instance;

  • The efficacy or side effects of unapproved drugs may not be known yet.
  • Pharmaceutical companies are not obliged to supply unapproved products and there is no tool to require companies to do so.
  • Patients may need to pay for the product personally. Therefore, the pharmaceutical may not be in the Institution's reimbursement list.
  • The procedure is complicated and onerous, so patients may experience long delays in receiving an answer from the Ministry.


1. http://www.titck.gov.tr/Haberler/HaberGetir?id=294

2. http://www.titck.gov.tr/Mevzuat/MevzuatGetir?id=2126

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Merve Altınay
Similar Articles
Relevancy Powered by MondaqAI
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions